Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Continuous glucose monitoring (CGM) has become a widely used tool in the ambulatory setting for monitoring glucose levels, as well as detecting uncontrolled hyperglycemia, hypoglycemia, and glycemic variability. The accuracy of some CGM systems has recently improved to the point of manufacture with factory calibration and Food and Drug Administration clearance for nonadjunctive use to dose insulin. In this commentary, we analyze the answers to six questions about what is needed to bring CGM into the hospital as a reliable, safe, and effective tool. The evidence to date indicates that CGM offers promise as an effective tool for monitoring hospitalized patients. During the current coronavirus disease 2019 crisis, we hope to provide guidance to healthcare professionals, who are seeking to reduce exposure to SARS-Cov-2, as well as preserve invaluable personal protective equipment. In this commentary, we address who, what, where, when, why, and how CGM can be adopted for inpatient use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During the coronavirus disease 2019 (COVID-19) pandemic, many institutions used CGM in ICU and non-ICU settings, with the aim of minimizing exposure time and saving personal protective equipment, under an FDA policy of enforcement discretion (49,50).”
From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data on the safety and efficacy of real-time CGM use in the hospital, particularly with implementation of remote monitoring (e.g., a glucose telemetry system), has grown (47,50-52).”
From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This approach has been taken to reduce the use of personal protective equipment and more closely monitor patients so that health care personnel do not have to go into a patient room solely to measure a glucose level (283-286).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [286]
The cited source says what the claim attributes to it.
In the citing paper
“Studies have been published assessing the effectiveness of this approach, which may ultimately lead to the approved use of CGM for monitoring hospitalized individuals (277,286-295).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [286]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The transition of persons from the hospital to ambulatory or subacute settings is a high-risk period for medication errors, but also an opportunity to improve glycemic control, avoiding what is often termed clinical inertia.102,1285,1286,1380”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1380]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sourcing Personal Protective Equipment During the COVID-19 Pandemic
Livingston, E., Desai, A., & Berkwits, M. (2020) · JAMA · doi:10.1001/jama.2020.5317 · Cited by 637
Wearable Devices for Ambulatory Cardiac Monitoring
Sana, F., Isselbacher, E. M., Singh, J. P., Heist, E. K., Pathik, B., & Armoundas, A. A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.046 · Cited by 362
Umpierrez, G., Cardona, S., Pasquel, F., Jacobs, S., Peng, L., Unigwe, M., Newton, C. A., Smiley-Byrd, D., Vellanki, P., Halkos, M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0303 · Cited by 281
Self-citation15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s015 · Cited by 265 · cited 1×
“13 The current recommended target glucose range in critically ill patients is 140-180 mg/dL. 17 It is difficult to achieve this range with multiple daily SC insulin injections, particularly in patients receiving vasoactive agents, high doses of steroids, or medical nutrition therapy (MNT).”
Khanna, A. K., Bergese, S. D., Jungquist, C. R., Morimatsu, H., Uezono, S., Lee, S., Ti, L. K., Urman, R. D., McIntyre, R., Tornero, C., et al. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004788 · Cited by 209
Downey, C. L., Chapman, S., Randell, R., Brown, J. M., & Jayne, D. G. (2018) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2018.04.013 · Cited by 185
Feldman, B., Brazg, R., Schwartz, S., & Weinstein, R. (2003) · Diabetes Technology & Therapeutics · doi:10.1089/152091503322526978 · Cited by 184 · cited 1×
“22 Ascorbic acid may falsely elevate sensor glucose readings, while aspirin may slightly lower glucose readings with FreeStyle Libre.”
Galindo, R. J., Migdal, A. L., Davis, G. M., Urrutia, M. A., Albury, B., Zambrano, C., Vellanki, P., Pasquel, F. J., Fayfman, M., Peng, L., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2073 · Cited by 181
Self-citationBergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700234 · Cited by 166
Self-citationConsensus Statement on Inpatient Use of Continuous Glucose Monitoring
Wallia, A., Umpierrez, G. E., Rushakoff, R. J., Klonoff, D. C., Rubin, D. J., Hill Golden, S., Cook, C. B., Thompson, B., & Panel, T. D. C. G. M. I. T. H. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817706151 · Cited by 147 · cited 1×
“13 The current recommended target glucose range in critically ill patients is 140-180 mg/dL. 17 It is difficult to achieve this range with multiple daily SC insulin injections, particularly in patients receiving vasoactive agents, high doses of steroids, or medical nutrition therapy (MNT).”
Self-citation
Research works printed but not linked: 4
- Nacoti M, 2020, NEJM Catal, 1
- Dexcom. Press release. https://www.dexcom.com/hospitalfacts. Accessed April 12, 2020.
- Abbott. Press release. https://abbott.mediaroom.com/2020-04-08-Abbotts-FreeStyle-R-Libre-14-Day-System-Now-Available-in-U-S-for-Hospitalized-Patients-with-Diabetes-During-COVID-19-Pandemic. Accessed April 12, 2020.
- Wake DJ, Eur J Endocrinol
Cited by
Electrochemical glucose sensors in diabetes management: an updated review (2010–2020)
Teymourian, H., Barfidokht, A., & Wang, J. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00304b · Cited by 881
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citation16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s016 · Cited by 440
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
“Studies are underway to assess the effectiveness of this approach, which may ultimately lead to the routine use of CGM for monitoring hospitalized patients (223,224).”
Background7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Self-citation
Metadata
- Authors
- Galindo, R. J., Aleppo, G., Klonoff, D. C., Spanakis, E. K., Agarwal, S., Vellanki, P., Olson, D. E., Umpierrez, G. E., Davis, G. M., & Pasquel, F. J.
- Affiliations
- Emory University (US)
- Northwestern University (US)
- San Mateo Medical Center (US)
- University of Maryland, Baltimore (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Pasquel, Francisco J.
- ORCID
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2020-06-14
- Volume
- 14
- Issue
- 4
- Pages
- 822-832
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC7673156
- OpenAlex
- W3034681791
- Cited by
- 155
- References
- 31
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 26 · 2023: 23 · 2022: 20 · 2021: 36 · 2020: 11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Diabetes Science and Technology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK-111024)
- national institutes of health (1K23DK123384-01, P30DK11102, K23DK115896, P30DK111022, 1K23DK113241, 1K23GM128221-01A1)
- VA MERIT (#1I01CX001825)
- NIH/NATS (UL1 TR002378, 1P30DK111024-01)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, hospital implementation, remote glucose monitoring, COVID-19 pandemic, personal protective equipment, hospitalized patients, glycemic variability, hypoglycemia, hyperglycemia, insulin dose, inpatient diabetes management
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Blood Glucose, Calibration, Communicable Disease Control, Diabetes Mellitus, Hospitalization, Hospitals, Humans, Hyperglycemia, Inpatients, Insulin Infusion Systems, Pneumonia, Viral, United States, United States Food and Drug Administration, Blood Glucose Self-Monitoring, Coronavirus Infections, Monitoring, Ambulatory, Diabetes Complications, Electronic Health Records, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic. https://app.cochat.ai/papers/10.1177/1932296820932903
- The paper
- Galindo, R. J., Aleppo, G., Klonoff, D. C., Spanakis, E. K., Agarwal, S., Vellanki, P., Olson, D. E., Umpierrez, G. E., Davis, G. M., & Pasquel, F. J. (2020). Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296820932903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.